In a patient with diabetic kidney disease, microalbuminuria, and an estimated glomerular filtration rate of 42 mL/min/1.73 m², can we initiate an angiotensin‑converting enzyme inhibitor (ACE inhibitor) or finerenone?

Yes, you can initiate both ACE inhibitors and finerenone in this patient with diabetic kidney disease, microalbuminuria, and eGFR 42 mL/min/1.73 m².

Start with an ACE inhibitor (or ARB) first, titrate to maximum tolerated dose, then add finerenone for additional kidney and cardiovascular protection. This sequential approach is supported by the most recent KDIGO 2022 and ADA 2025 guidelines 1, 2.

ACE Inhibitor Initiation at eGFR 42

An eGFR of 42 mL/min/1.73 m² (CKD stage 3b) is not a contraindication to starting an ACE inhibitor. The KDIGO 2022 guidelines explicitly recommend initiating ACEi/ARB in patients with diabetes, albuminuria (including microalbuminuria), and hypertension, with titration to the highest approved tolerated dose 1. Even in normotensive patients with diabetic kidney disease and albuminuria, ACEi/ARB treatment may be considered 1.

Monitoring Protocol for ACEi

When initiating an ACEi at this eGFR level:

• Check serum creatinine and potassium within 2-4 weeks of initiation or dose increase 1
• Continue therapy unless creatinine rises >30% within 4 weeks of starting treatment 1
• A creatinine increase <30% is expected hemodynamic effect and should not prompt discontinuation 1
• Manage hyperkalemia with dietary potassium restriction, volume correction, and medication review rather than immediately stopping the ACEi 1
• Only reduce dose or stop if: symptomatic hypotension, uncontrolled hyperkalemia despite medical management, or uremic symptoms with eGFR <15 1

Critical Caveat for ACEi Use

Review for bilateral renal artery stenosis if creatinine rises >30%, as this is a contraindication. Also assess for concurrent nephrotoxic medications (NSAIDs, diuretics causing volume depletion) that could contribute to acute kidney injury 1.

Finerenone Addition

Finerenone should be added after ACEi/ARB is optimized, as this provides complementary kidney and cardiovascular protection. The ADA 2025 guidelines position finerenone as the nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) with proven clinical kidney and cardiovascular benefits 2.

Finerenone Eligibility at eGFR 42

• eGFR 42 is within the approved range: Finerenone has been studied and shown benefit in patients with eGFR ≥25 mL/min/1.73 m² 3
• Recent real-world evidence demonstrates finerenone reduces albuminuria by approximately 34% over 6 months when added to ACEi/ARB therapy 4
• The combination of ACEi/ARB plus finerenone provides greater albuminuria reduction (mean UACR decrease from 478 to 143 mg/gCr) compared to finerenone alone 5

Finerenone Dosing at eGFR 42

At eGFR 42 mL/min/1.73 m², use finerenone 10 mg daily initially (the lower dose is used when eGFR is 25-60 mL/min/1.73 m²) 3. The dose can be increased to 20 mg daily if eGFR improves to >60 or if tolerated without hyperkalemia.

Monitoring for Finerenone

• Primary concern is hyperkalemia: Occurs in approximately 10% of patients on finerenone plus ACEi/ARB 3
• Check potassium within 4 weeks of initiation 6
• Mean potassium increase is modest (0.3 mEq/L at 6 months) 6
• Discontinuation rate due to hyperkalemia is approximately 5.4% in real-world practice 6
• Expect initial eGFR dip: A reversible decrease in eGFR may occur (mean -5.6 mL/min/1.73 m² at 6 months), which typically approaches baseline during washout and is not an indication to stop 3, 4

Sequential Treatment Algorithm

1. Initiate ACEi (or ARB if ACEi not tolerated due to cough)
2. Titrate to maximum tolerated dose over 4-8 weeks
3. Monitor creatinine and potassium at 2-4 weeks after each dose adjustment
4. Once ACEi/ARB is optimized, add finerenone 10 mg daily
5. Check potassium within 4 weeks of adding finerenone
6. Continue both agents unless hyperkalemia becomes unmanageable or creatinine rises >30% acutely

Additional Considerations

Add an SGLT2 inhibitor if the patient has type 2 diabetes, as KDIGO 2022 strongly recommends SGLT2i for patients with eGFR ≥20 mL/min/1.73 m² for kidney and cardiovascular protection 1. The combination of ACEi/ARB + SGLT2i + finerenone represents the current standard of care for diabetic kidney disease 2.

The evidence strongly supports using both ACEi and finerenone in this clinical scenario, with careful monitoring for hyperkalemia and acute changes in kidney function being the main safety considerations.